VaV1 (A168) polyclonal Antibody | BS1370

VaV1 (A168) polyclonal Antibody | BS1370 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200

Background: The Vav gene was originally identified on the basis of its oncogenic activation during the course of gene transfer assays. The major translational product of the Vav proto-oncogene has been identified as a protein containing an array of structural motifs. Contained within its amino terminus are a helix-loop-helix domain and a leucine zipper motif similar to that of Myc family proteins; deletion of this region of p95Vav causes its oncogenic activation. In addition, p95Vav contains an SH2 domain, which could indicate its role as a substrate for tyrosine kinases. Expression of p95Vav is limited exclusively to cells of hematopoietic origin, including those of the erythroid, lymphoid and myeloid lineages.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: VAV1 (A168) polyclonal Antibody detects endogenous levels of VAV1 protein.

Molecular Weight: ~ 100 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Proto-oncogene vav; VAV1; VAV

Immunogen: Synthetic peptide, corresponding to amino acids 140-190 of Human VaV1.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Tumor Angiogenesis,ErbB HER Signaling,ErbB HER Signaling,